Key Highlights

● Kamada declared a Cash Dividend of $0.17 per share on Aug. 17, 2026, paid Sept. 17, 2026, a total distribution of approximately $9.8 million.

● The verified $0.17 annual dividend implies a Yield closer to 2% at a share price near $8.29, well below the roughly 5.2% trailing figure some screens show.

● Kamada pays its dividend annually rather than quarterly, so a single payment represents the year's full cash return to shareholders.

● The company reported record-high Revenue and profitability for the first six months of 2026, supporting the payout.

Kamada Ltd. (Nasdaq:KMDA) surfaced on income screens with a mid-single-digit trailing yield, an eye-catching figure for a specialty pharmaceutical company. But dividends are central to any income thesis, and in Kamada's case the headline number does not line up cleanly with the company's actual payout. The Israel-based maker of plasma-derived therapies pays a modest annual dividend, and the gap between a screener's figure and the verified distribution is the first thing income investors should understand.

The Latest Dividend

On August 17, 2026, Kamada declared a cash dividend of $0.17 per share, roughly NIS 0.50, payable September 17, 2026 to shareholders of record on August 27, 2026. The total distribution amounts to approximately $9.8 million. The company described the payment as consistent with its dividend policy. Unlike many U.S. corporations that pay quarterly, Kamada distributes its dividend annually, so this single payment represents the year's cash return to shareholders.

Why the Trailing Yield Needs Context

Some screens have shown a trailing yield near 5.2% for KMDA. That figure is difficult to reconcile with a verified annual dividend of $0.17 per share, which at a price near $8.29 implies a yield closer to 2%. Investors should therefore treat any higher headline figure with caution and distinguish it from the company's current indicated payout. Because Kamada pays once a year, its dividend does not compound through the year the way a quarterly payer's does, and headline trailing calculations can mislead.

A Young Dividend History

Kamada's status as a dividend payer is relatively recent; the company introduced Shareholder distributions as its profitability improved, rather than maintaining a long, multi-year record of increases. That makes the payout less a fixed commitment and more a reflection of how management balances cash returns against reinvestment in its plasma and biopharmaceutical pipeline. Income investors should not assume a guaranteed escalation from one annual payment to the next.

Financial Backdrop

Kamada is a global biopharmaceutical company focused on specialty plasma-derived therapies for rare and serious conditions. Alongside the dividend, it reported record-high revenue and profitability for the first six months of 2026. The Business spans FDA-approved specialty plasma products, distribution of third-party pharmaceuticals in Israel and the MENA region, and plasma-collection centers in Texas. Improving cash generation is what has allowed the company to sustain a dividend at all. Set once a year against annual profitability rather than smoothed across quarters, its size reflects the prior period's results more than a standing commitment.

Why Income Investors Are Watching

For income-focused investors, Kamada is less a high-yield play than a growth-oriented healthcare company that happens to pay a small, policy-linked dividend. The appeal lies in the combination of a specialized, defensible product niche and a payout that could grow if profitability continues to build. The rare-disease and plasma-therapy markets tend to be less cyclical than broader industrials, which can lend some stability to earnings.

Risks

The risks are those of a mid-cap specialty pharmaceutical firm. Regulatory approvals, plasma supply, product concentration and competition all bear on earnings, and therefore on the dividend. Currency movement between the shekel and the dollar affects both reported results and the dollar value of the payout. Because the dividend is annual and policy-driven, it can be adjusted or skipped in a weaker year without breaking a quarterly cadence. That flexibility protects the Balance Sheet in a lean year, but investors cannot lean on it as they might on an established quarterly compounder.

A Growth Story With a Small Dividend Attached

Kamada's verified dividend is a modest $0.17 per share paid annually, implying a yield well below some higher headline figures that circulate for the stock. The company is better understood as a profitable, growing plasma-therapy specialist than as a high-income vehicle. Investors drawn by a screen yield should confirm the current payout for themselves, and remember that a headline number is a poor guide on its own.